038070 — Seoulin Bioscience Co Income Statement
0.000.00%
- KR₩71bn
- KR₩46bn
- KR₩90bn
Annual income statement for Seoulin Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 54,410 | 65,085 | 80,539 | 104,708 | 89,569 |
Cost of Revenue | |||||
Gross Profit | 13,865 | 16,566 | 21,104 | 24,349 | 19,921 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 53,963 | 60,616 | 74,494 | 96,024 | 89,404 |
Operating Profit | 446 | 4,469 | 6,045 | 8,684 | 166 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 10,659 | 5,782 | 20,338 | 14,029 | -1,929 |
Provision for Income Taxes | |||||
Net Income After Taxes | 8,887 | 4,801 | 15,879 | 10,565 | -2,323 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 8,884 | 4,893 | 15,589 | 10,159 | -118 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 8,884 | 4,893 | 15,589 | 10,159 | -118 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1,150 | 569 | 2,003 | 1,014 | 169 |
Dividends per Share |